Lilly's baricitinib stunner helps Pfizer—and AbbVie, too by Tracy Staton Monday, April 17, 2017 Pfizer's Xeljanz is an obvious beneficiary of Eli Lilly's surprise Olumiant (baricitinib) rejection at the FDA. But AbbVie and Gilead could gain, too.
